Your browser doesn't support javascript.
loading
Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals.
Otter, Ashley D; Jones, Scott; Hicks, Bethany; Bailey, Daniel; Callaby, Helen; Houlihan, Catherine; Rampling, Tommy; Gordon, Nicola Claire; Selman, Hannah; Satheshkumar, Panayampalli S; Townsend, Michael; Mehta, Ravi; Pond, Marcus; Jones, Rachael; Wright, Deborah; Oeser, Clarissa; Tonge, Simon; Linley, Ezra; Hemingway, Georgia; Coleman, Tom; Millward, Sebastian; Lloyd, Aaron; Damon, Inger; Brooks, Tim; Vipond, Richard; Rowe, Cathy; Hallis, Bassam.
Affiliation
  • Otter AD; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK. ashley.otter@ukhsa.gov.uk.
  • Jones S; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Hicks B; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Bailey D; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Callaby H; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Houlihan C; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Rampling T; Department of Infection and Immunity, University College London, London, UK.
  • Gordon NC; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Selman H; The Hospital for Tropical Diseases, University College London Hospital, London, UK.
  • Satheshkumar PS; NIHR University College London Hospitals BRC, London, UK.
  • Townsend M; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Mehta R; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Pond M; Poxvirus and Rabies Branch, Centre for Disease Control and Prevention, Atlanta, GA, USA.
  • Jones R; Poxvirus and Rabies Branch, Centre for Disease Control and Prevention, Atlanta, GA, USA.
  • Wright D; Imperial College Healthcare NHS Trust, London, UK.
  • Oeser C; Imperial College Healthcare NHS Trust, London, UK.
  • Tonge S; Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
  • Linley E; Research and Development, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Hemingway G; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, Colindale, London, UK.
  • Coleman T; Seroepidemiology Unit, UK Health Security Agency, Manchester, UK.
  • Millward S; Seroepidemiology Unit, UK Health Security Agency, Manchester, UK.
  • Lloyd A; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Damon I; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Brooks T; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Vipond R; Emerging Pathogen Serology group, UK Health Security Agency, Porton Down, Wiltshire, UK.
  • Rowe C; Poxvirus and Rabies Branch, Centre for Disease Control and Prevention, Atlanta, GA, USA.
  • Hallis B; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK.
Nat Commun ; 14(1): 5948, 2023 Sep 23.
Article in En | MEDLINE | ID: mdl-37741831
ABSTRACT
In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case numbers exceeding 80,000 were reported worldwide, primarily affecting gay, bisexual, and other men who have sex with men (GBMSM). Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals at high-risk to provide protection and limit the spread of MPXV. We have developed a comprehensive array of ELISAs to study poxvirus-induced antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of serum samples from individuals with differing Smallpox-vaccine doses and those with prior MPXV infection were tested on these assays, where we observed that one dose of Smallpox vaccination induces a low number of antibodies to a limited number of MPXV antigens but increasing with further vaccination doses. MPXV infection induced similar antibody responses to diverse poxvirus antigens observed in Smallpox-vaccinated individuals. We identify MPXV A27 as a serological marker of MPXV-infection, whilst MPXV M1 (VACV L1) is likely IMVANEX-specific. Here, we demonstrate analogous humoral antigen recognition between both MPXV-infected or Smallpox-vaccinated individuals, with binding to diverse yet core set of poxvirus antigens, providing opportunities for future vaccine (e.g., mRNA) and therapeutic (e.g., mAbs) design.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Smallpox / Smallpox Vaccine / Sexual and Gender Minorities Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Smallpox / Smallpox Vaccine / Sexual and Gender Minorities Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country: United kingdom